Mobocertinib succinate

Modify Date: 2024-01-29 22:22:49

Mobocertinib succinate structure	Common Name	Mobocertinib succinate
	CAS Number	2389149-74-8	Molecular Weight	703.78
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₃₆H₄₅N₇O₈	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Mobocertinib succinate

Mobocertinib succinate (compound A) is a potent epidermal growth factor receptor (EGFR) inhibitor and an antineoplastic agent, extracted from patent WO2019222093A1, compound A[1][2].

Name	Mobocertinib succinate
Synonym	More Synonyms

Description	Mobocertinib succinate (compound A) is a potent epidermal growth factor receptor (EGFR) inhibitor and an antineoplastic agent, extracted from patent WO2019222093A1, compound A[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR
References	[1]. International Nonproprietary Names for Pharmaceutical Substances (INN). [2]. Landon J. DURAK, et al. Pharmaceutical salts of pyrimidine derivatives and method of treating disorders. WO2019222093A1.

Description

Mobocertinib succinate (compound A) is a potent epidermal growth factor receptor (EGFR) inhibitor and an antineoplastic agent, extracted from patent WO2019222093A1, compound A[1][2].

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> JAK/STAT Signaling >> EGFR

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR

References

[1]. International Nonproprietary Names for Pharmaceutical Substances (INN).

[2]. Landon J. DURAK, et al. Pharmaceutical salts of pyrimidine derivatives and method of treating disorders. WO2019222093A1.